Ruxolitinib, also known as ruxolitinib in China, is one of the “new drugs” that have been widely listed in clinical guidelines for the treatment of hematological diseases in recent years, and has shown promising efficacy in myeloproliferative diseases.The targeted drug Jakavi ruxolitinib can effectively inhibit the activation of the entire JAK-STAT channel and reduce the […]
